The deal – financial terms of which were not disclosed – will see Selexis integrated into KBI Biopharma, a contract development and manufacturing organization JSR and partners CMIC Holdings Co., Innovation Network Corporation of Japan (INCJ) bought in 2015.
Selexis’ core business is based on its SUREtechnology Platform, which is used to generate cell lines for the production of recombinant proteins.
According to JSR “KBI has performed development and or manufacturing services using more than 15 different Selexis generated cell lines since 2012.”
News of the acquisition comes a few weeks after JSR announced its intention to spend $30m (€26m) to expand its biopharmaceutical manufacturing facilities in Durham, North Carolina and Boulder, Colorado.
In addition, KBI recently acquired a cell therapy manufacturing facility in Texas, and has previously announced plans to open an analytical services laboratory in Belgium.